☆ 4.6 Article

Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: The DEBBRAH trial

NEURO-ONCOLOGY (2023)

Related references

Note: Only part of the references are listed.

Article Medicine, General & Internal

Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer

J. Cortes et al.

Summary: Among patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and a taxane, trastuzumab deruxtecan was associated with a lower risk of disease progression or death compared to trastuzumab emtansine. However, treatment with trastuzumab deruxtecan was associated with interstitial lung disease and pneumonitis.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Article Oncology

ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer

A. Gennari et al.

ANNALS OF ONCOLOGY (2021)

Add to Collection

Review Oncology

Treatment strategies for breast cancer brain metastases

Caroline Bailleux et al.

Summary: Brain metastases from breast cancer are becoming more common and represent a major therapeutic challenge. Surgery and stereotaxic radiosurgery are effective for controlling BCBM.

BRITISH JOURNAL OF CANCER (2021)

Add to Collection

Review Oncology

Breast Cancer Brain Metastasis-Overview of Disease State, Treatment Options and Future Perspectives

Chikashi Watase et al.

Summary: Brain metastases from breast cancer often occur in advanced stage patients with poor prognosis. Local treatments and new targeted therapies play crucial roles in improving clinical outcomes.

CANCERS (2021)

Add to Collection

Review Oncology

How we treat HER2-positive brain metastases

E. Stavrou et al.

Summary: The overexpression of the HER2/neu receptor in breast cancer is associated with an increased risk of brain metastases, especially in advanced cases. Management of HER2-positive brain metastases often involves surgery, radiation, and systemic therapies by an experienced multidisciplinary team, and poses unique clinical challenges in prevention and treatment.

ESMO OPEN (2021)

Add to Collection

Review Oncology

Brain Metastases in HER2-Positive Breast Cancer: Current and Novel Treatment Strategies

Alejandro Garcia-Alvarez et al.

Summary: Development of brain metastases is a significant event for patients with breast cancer, particularly those with HER2-positive tumors. Advances in targeted therapy against the HER2 receptor have improved management of HER2-positive breast cancer. Despite these improvements, brain metastases continue to be a challenge, highlighting the need for further research and innovative treatment strategies.

CANCERS (2021)

Add to Collection

Letter Oncology

Exclusion of patients with brain metastases from cancer clinical trials

Roshal R. Patel et al.

NEURO-ONCOLOGY (2020)

Add to Collection

Article Medicine, General & Internal

Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer

R. K. Murthy et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Medicine, General & Internal

Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer

Shanu Modi et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Oncology

Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial

Nancy U. Lin et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

Add to Collection

Article Oncology

Central Nervous System Metastasis in Patients with HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from SystHERs

Sara A. Hurvitz et al.

CLINICAL CANCER RESEARCH (2019)

Add to Collection

Review Oncology

Clinical trial design for systemic agents in patients with brain metastases from solid tumours: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group

D. Ross Camidge et al.

LANCET ONCOLOGY (2018)

Add to Collection

Article Oncology

Systemic therapy of brain metastases: non-small cell lung cancer, breast cancer, and melanoma

Marc C. Chamberlain et al.

NEURO-ONCOLOGY (2017)

Add to Collection

Article Oncology

Modernizing Clinical Trial Eligibility Criteria: Recommendations of the American Society of Clinical Oncology-Friends of Cancer Research Brain Metastases Working Group

Nancy U. Lin et al.

JOURNAL OF CLINICAL ONCOLOGY (2017)

Add to Collection

Article Oncology

Broadening Eligibility Criteria to Make Clinical Trials More Representative: American Society of Clinical Oncology and Friends of Cancer Research Joint Research Statement

Edward S. Kim et al.

JOURNAL OF CLINICAL ONCOLOGY (2017)

Add to Collection

Article Oncology

Activity of T-DM1 in Her2-positive breast cancer brain metastases

Rupert Bartsch et al.

CLINICAL & EXPERIMENTAL METASTASIS (2015)

Add to Collection

Article Medicine, Research & Experimental

Statistical issues for design and analysis of single-arm multi-stage phase II cancer clinical trials

Sin-Ho Jung

CONTEMPORARY CLINICAL TRIALS (2015)

Add to Collection

Review Oncology

Breast cancer brain metastases: the last frontier

Jose Pablo Leone et al.

EXPERIMENTAL HEMATOLOGY & ONCOLOGY (2015)

Add to Collection

Article Oncology

Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study

Thomas Bachelot et al.

LANCET ONCOLOGY (2013)

Add to Collection

© Peeref 2019-2024. All rights reserved.